Huan Yang

Company: Merck & Co

Job title: Associate Principal Scientist

Seminars:

Panel Discussion: Brainstorming Combinations With CART, DDR, Cytokine-Based Therapies & Other Cell Engagers 9:30 am

Discuss potential benefits and risks of combining cell engagers with alternate cancer therapies for personalized treatment strategies How can cell engager combinations be developed to reduce potential relapse while reducing the patient burden of treatment? Can these combinations mitigate T cell exhaustion to improve efficacy across cancer types and reduce patient burden?Read more

day: Conference Day 2